{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,18]],"date-time":"2026-04-18T03:04:39Z","timestamp":1776481479276,"version":"3.51.2"},"reference-count":44,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2021,1,7]],"date-time":"2021-01-07T00:00:00Z","timestamp":1609977600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2021,1,7]],"date-time":"2021-01-07T00:00:00Z","timestamp":1609977600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100011110","name":"UCB","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100011110","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100002429","name":"Amgen","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002429","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Osteoporos Int"],"published-print":{"date-parts":[[2021,7]]},"DOI":"10.1007\/s00198-020-05765-7","type":"journal-article","created":{"date-parts":[[2021,1,7]],"date-time":"2021-01-07T06:04:15Z","timestamp":1609999455000},"page":"1301-1311","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":16,"title":["A novel economic framework to assess the cost-effectiveness of bone-forming agents in the prevention of fractures in patients with osteoporosis"],"prefix":"10.1007","volume":"32","author":[{"given":"E.","family":"S\u00f6reskog","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"F.","family":"Borgstr\u00f6m","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6549-6065","authenticated-orcid":false,"given":"I.","family":"Lindberg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"O.","family":"Str\u00f6m","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D.","family":"Willems","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.","family":"Libanati","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J. A.","family":"Kanis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"B.","family":"Stollenwerk","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Charokopou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,1,7]]},"reference":[{"issue":"12","key":"5765_CR1","doi-asserted-by":"publisher","first-page":"1726","DOI":"10.1007\/s00198-006-0172-4","volume":"17","author":"O Johnell","year":"2006","unstructured":"Johnell O, Kanis JA (2006) An estimate of the worldwide prevalence and disability associated with osteoporotic fractures. Osteoporos Int 17(12):1726\u20131733","journal-title":"Osteoporos Int"},{"key":"5765_CR2","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1007\/s11657-013-0136-1","volume":"8","author":"E Hernlund","year":"2013","unstructured":"Hernlund E, Svedbom A, Ivergard M, Compston J, Cooper C, Stenmark J, McCloskey EV, Jonsson B, Kanis JA (2013) Osteoporosis in the European Union: medical management, epidemiology and economic burden. A report prepared in collaboration with the International Osteoporosis Foundation (IOF) and the European Federation of Pharmaceutical Industry Associations (EFPIA). Arch Osteoporos 8:136","journal-title":"Arch Osteoporos"},{"issue":"3","key":"5765_CR3","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1007\/s00198-019-04852-8","volume":"30","author":"J Banefelt","year":"2019","unstructured":"Banefelt J, \u00c5kesson KE, Sp\u00e5ng\u00e9us A, Ljunggren O, Karlsson L, Str\u00f6m O, Orts\u00e4ter G, Libanati C, Toth E (2019) Risk of imminent fracture following a previous fracture in a Swedish database study. Osteoporos Int 30(3):601\u2013609","journal-title":"Osteoporos Int"},{"issue":"11","key":"5765_CR4","doi-asserted-by":"publisher","first-page":"2317","DOI":"10.1002\/jbmr.1968","volume":"28","author":"D Bliuc","year":"2013","unstructured":"Bliuc D, Nguyen ND, Nguyen TV, Eisman JA, Center JR (2013) Compound risk of high mortality following osteoporotic fracture and refracture in elderly women and men. J Bone Miner Res 28(11):2317\u20132324","journal-title":"J Bone Miner Res"},{"issue":"3","key":"5765_CR5","doi-asserted-by":"publisher","first-page":"775","DOI":"10.1007\/s00198-016-3868-0","volume":"28","author":"H Johansson","year":"2017","unstructured":"Johansson H, Siggeirsdottir K, Harvey NC, Oden A, Gudnason V, McCloskey E, Sigurdsson G, Kanis JA (2017) Imminent risk of fracture after fracture. Osteoporos Int 28(3):775\u2013780","journal-title":"Osteoporos Int"},{"issue":"1","key":"5765_CR6","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1136\/ard.2008.092775","volume":"68","author":"TA van Geel","year":"2009","unstructured":"van Geel TA, van Helden S, Geusens PP, Winkens B, Dinant GJ (2009) Clinical subsequent fractures cluster in time after first fractures. Ann Rheum Dis 68(1):99\u2013102","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"5765_CR7","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s00198-019-05176-3","volume":"31","author":"JA Kanis","year":"2020","unstructured":"Kanis JA, Harvey NC, McCloskey E, Bruyere O, Veronese N, Lorentzon M, Cooper C, Rizzoli R, Adib G, Al-Daghri N, Campusano C, Chandran M, Dawson-Hughes B, Javaid K, Jiwa F, Johansson H, Lee JK, Liu E, Messina D, Mkinsi O, Pinto D, Prieto-Alhambra D, Saag K, Xia W, Zakraoui L, Reginster J (2020) Algorithm for the management of patients at low, high and very high risk of osteoporotic fractures. Osteoporos Int 31(1):1\u201312","journal-title":"Osteoporos Int"},{"issue":"1","key":"5765_CR8","doi-asserted-by":"publisher","first-page":"46","DOI":"10.5152\/eurjrheum.2016.048","volume":"4","author":"T Sozen","year":"2017","unstructured":"Sozen T, Ozisik L, Basaran NC (2017) An overview and management of osteoporosis. Eur J Rheumatol 4(1):46\u201356","journal-title":"Eur J Rheumatol"},{"issue":"2","key":"5765_CR9","first-page":"97","volume":"56","author":"JY Reginster","year":"2014","unstructured":"Reginster JY, Neuprez A, Beaudart C, Buckinx F, Slomian J, Disteche S, Bruyere O (2014) Bone forming agents for the management of osteoporosis. Panminerva Med 56(2):97\u2013114","journal-title":"Panminerva Med"},{"issue":"10117","key":"5765_CR10","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1016\/S0140-6736(17)32137-2","volume":"391","author":"DL Kendler","year":"2018","unstructured":"Kendler DL, Marin F, Zerbini CAF, Russo LA, Greenspan SL, Zikan V, Bagur A, Malouf-Sierra J, Lakatos P, Fahrleitner-Pammer A, Lespessailles E, Minisola S, Body JJ, Geusens P, Moricke R, Lopez-Romero P (2018) Effects of teriparatide and risedronate on new fractures in post-menopausal women with severe osteoporosis (VERO): a multicentre, double-blind, double-dummy, randomised controlled trial. Lancet 391(10117):230\u2013240","journal-title":"Lancet"},{"issue":"15","key":"5765_CR11","doi-asserted-by":"publisher","first-page":"1417","DOI":"10.1056\/NEJMoa1708322","volume":"377","author":"KG Saag","year":"2017","unstructured":"Saag KG, Petersen J, Brandi ML, Karaplis AC, Lorentzon M, Thomas T, Maddox J, Fan M, Meisner PD, Grauer A (2017) Romosozumab or alendronate for fracture prevention in women with osteoporosis. N Engl J Med 377(15):1417\u20131427","journal-title":"N Engl J Med"},{"issue":"5","key":"5765_CR12","doi-asserted-by":"publisher","first-page":"1623","DOI":"10.1210\/jc.2019-00192","volume":"104","author":"P Barrionuevo","year":"2019","unstructured":"Barrionuevo P, Kapoor E, Asi N, Alahdab F, Mohammed K, Benkhadra K, Almasri J, Farah W, Sarigianni M, Muthusamy K, Al Nofal A, Haydour Q, Wang Z, Murad MH (2019) Efficacy of pharmacological therapies for the prevention of fractures in postmenopausal women: a network meta-analysis. J Clin Endocrinol Metab 104(5):1623\u20131630","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"5765_CR13","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1007\/s00198-018-4790-4","volume":"30","author":"S Lou","year":"2019","unstructured":"Lou S, Lv H, Yin P, Li Z, Tang P, Wang Y (2019) Combination therapy with parathyroid hormone analogs and antiresorptive agents for osteoporosis: a systematic review and meta-analysis of randomized controlled trials. Osteoporos Int 30(1):59\u201370","journal-title":"Osteoporos Int"},{"key":"5765_CR14","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.bone.2018.09.020","volume":"120","author":"A Diez-Perez","year":"2019","unstructured":"Diez-Perez A, Marin F, Eriksen EF, Kendler DL, Krege JH, Delgado-Rodriguez M (2019) Effects of teriparatide on hip and upper limb fractures in patients with osteoporosis: a systematic review and meta-analysis. Bone 120:1\u20138","journal-title":"Bone"},{"issue":"8","key":"5765_CR15","doi-asserted-by":"publisher","first-page":"2949","DOI":"10.1210\/jc.2018-00163","volume":"103","author":"HG Bone","year":"2018","unstructured":"Bone HG, Cosman F, Miller PD, Williams GC, Hattersley G, Hu M-y, Fitzpatrick LA, Mitlak B, Papapoulos S, Rizzoli R (2018) ACTIVExtend: 24 months of alendronate after 18 months of abaloparatide or placebo for postmenopausal osteoporosis. The Journal of Clinical Endocrinology & Metabolism 103(8):2949\u20132957","journal-title":"The Journal of Clinical Endocrinology & Metabolism"},{"issue":"4","key":"5765_CR16","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1007\/s00198-007-0543-5","volume":"19","author":"JA Kanis","year":"2008","unstructured":"Kanis JA, Johnell O, Oden A, Johansson H, McCloskey E (2008) FRAX and the assessment of fracture probability in men and women from the UK. Osteoporos Int 19(4):385\u2013397","journal-title":"Osteoporos Int"},{"key":"5765_CR17","doi-asserted-by":"crossref","unstructured":"Soreskog E, Strom O, Spangeus A, Akesson KE, Borgstrom F, Banefelt J, Toth E, Libanati C, Charokopou M (2020) Risk of major osteoporotic fracture after first, second and third fracture in Swedish women aged 50 years and older. Bone 134:115286","DOI":"10.1016\/j.bone.2020.115286"},{"key":"5765_CR18","unstructured":"Kanis JA (2008) Assessment of osteoporosis at the primary health-care level. Technical Report. WHO Collaborating Centre, University of Sheffield, UK"},{"issue":"2","key":"5765_CR19","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1007\/s40520-019-01432-y","volume":"32","author":"JA Kanis","year":"2020","unstructured":"Kanis JA, Harvey NC, Johansson H, Liu E, Vandenput L, Lorentzon M, Leslie WD, McCloskey EV (2020) A decade of FRAX: how has it changed the management of osteoporosis? Aging Clin Exp Res 32(2):187\u2013196","journal-title":"Aging Clin Exp Res"},{"issue":"2","key":"5765_CR20","doi-asserted-by":"publisher","first-page":"430","DOI":"10.1016\/j.bone.2010.05.020","volume":"47","author":"O Strom","year":"2010","unstructured":"Strom O, Borgstrom F, Kleman M, McCloskey E, Oden A, Johansson H, Kanis JA (2010) FRAX and its applications in health economics--cost-effectiveness and intervention thresholds using bazedoxifene in a Swedish setting as an example. Bone 47(2):430\u2013437","journal-title":"Bone"},{"key":"5765_CR21","unstructured":"Davis S (2015) Bisphosphonates for preventing osteoporotic fragility fractures (including a partial update of NICE technology appraisal guidance 160 and 161). Assessment report. Table 32., National Institute for Health and Care Excellence (NICE), Editor"},{"issue":"3","key":"5765_CR22","doi-asserted-by":"publisher","first-page":"967","DOI":"10.1007\/s00198-010-1424-x","volume":"22","author":"B Jonsson","year":"2011","unstructured":"Jonsson B, Strom O, Eisman JA, Papaioannou A, Siris ES, Tosteson A, Kanis JA (2011) Cost-effectiveness of denosumab for the treatment of postmenopausal osteoporosis. Osteoporos Int 22(3):967\u2013982","journal-title":"Osteoporos Int"},{"issue":"3","key":"5765_CR23","doi-asserted-by":"publisher","first-page":"381","DOI":"10.3111\/13696998.2010.499072","volume":"13","author":"F Borgstrom","year":"2010","unstructured":"Borgstrom F, Strom O, Marin F, Kutahov A, Ljunggren O (2010) Cost effectiveness of teriparatide and PTH(1-84) in the treatment of postmenopausal osteoporosis. J Med Econ 13(3):381\u2013392","journal-title":"J Med Econ"},{"issue":"1","key":"5765_CR24","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1007\/s00198-008-0644-9","volume":"20","author":"O Strom","year":"2009","unstructured":"Strom O, Borgstrom F, Kanis JA, Jonsson B (2009) Incorporating adherence into health economic modelling of osteoporosis. Osteoporos Int 20(1):23\u201334","journal-title":"Osteoporos Int"},{"issue":"1","key":"5765_CR25","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1007\/s00198-018-4744-x","volume":"30","author":"M Hiligsmann","year":"2019","unstructured":"Hiligsmann M, Reginster JY, Tosteson ANA, Bukata SV, Saag KG, Gold DT, Halbout P, Jiwa F, Lewiecki EM, Pinto D, Adachi JD, Al-Daghri N, Bruyere O, Chandran M, Cooper C, Harvey NC, Einhorn TA, Kanis JA, Kendler DL, Messina OD, Rizzoli R, Si L, Silverman S (2019) Recommendations for the conduct of economic evaluations in osteoporosis: outcomes of an experts\u2019 consensus meeting organized by the European Society for Clinical and Economic Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (ESCEO) and the US branch of the International Osteoporosis Foundation. Osteoporos Int 30(1):45\u201357","journal-title":"Osteoporos Int"},{"issue":"6","key":"5765_CR26","doi-asserted-by":"publisher","first-page":"1064","DOI":"10.1016\/j.bone.2003.12.028","volume":"34","author":"F Borgstrom","year":"2004","unstructured":"Borgstrom F, Johnell O, Jonsson B, Zethraeus N, Sen SS (2004) Cost effectiveness of alendronate for the treatment of male osteoporosis in Sweden. Bone 34(6):1064\u20131071","journal-title":"Bone"},{"key":"5765_CR27","unstructured":"Office for National Statistics National Life Tables, Great Britain. 2012-2014. Central rate of mortality, females"},{"issue":"5","key":"5765_CR28","doi-asserted-by":"publisher","first-page":"468","DOI":"10.1016\/S8756-3282(03)00061-9","volume":"32","author":"JA Kanis","year":"2003","unstructured":"Kanis JA, Oden A, Johnell O, De Laet C, Jonsson B, Oglesby AK (2003) The components of excess mortality after hip fracture. Bone 32(5):468\u2013473","journal-title":"Bone"},{"issue":"2","key":"5765_CR29","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1007\/s00198-003-1516-y","volume":"15","author":"JA Kanis","year":"2004","unstructured":"Kanis JA, Oden A, Johnell O, De Laet C, Jonsson B (2004) Excess mortality after hospitalisation for vertebral fracture. Osteoporos Int 15(2):108\u2013112","journal-title":"Osteoporos Int"},{"issue":"2","key":"5765_CR30","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1007\/s00198-011-1549-6","volume":"23","author":"E Landfeldt","year":"2012","unstructured":"Landfeldt E, Strom O, Robbins S, Borgstrom F (2012) Adherence to treatment of primary osteoporosis and its association to fractures--the Swedish Adherence Register Analysis (SARA). Osteoporos Int 23(2):433\u2013443","journal-title":"Osteoporos Int"},{"issue":"1","key":"5765_CR31","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1007\/s11657-017-0316-5","volume":"12","author":"E Durden","year":"2017","unstructured":"Durden E, Pinto L, Lopez-Gonzalez L, Juneau P, Barron R (2017) Two-year persistence and compliance with osteoporosis therapies among postmenopausal women in a commercially insured population in the United States. Arch Osteoporos 12(1):22","journal-title":"Arch Osteoporos"},{"issue":"1","key":"5765_CR32","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1007\/s11657-015-0222-7","volume":"10","author":"E Jonsson","year":"2015","unstructured":"Jonsson E, Eriksson D, \u00c5kesson K, Ljunggren \u00d6, Salomonsson S, Borgstr\u00f6m F, Str\u00f6m O (2015) Swedish osteoporosis care. Arch Osteoporos 10(1):24","journal-title":"Arch Osteoporos"},{"issue":"1","key":"5765_CR33","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1097\/gme.0b013e318221bacd","volume":"19","author":"L Li","year":"2012","unstructured":"Li L, Roddam A, Gitlin M, Taylor A, Shepherd S, Shearer A, Jick S (2012) Persistence with osteoporosis medications among postmenopausal women in the UK General Practice Research Database. Menopause 19(1):33\u201340","journal-title":"Menopause"},{"issue":"3","key":"5765_CR34","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1007\/s00198-017-4317-4","volume":"29","author":"A Svedbom","year":"2018","unstructured":"Svedbom A, Borgstom F, Hernlund E, Strom O, Alekna V, Bianchi ML, Clark P, Curiel MD, Dimai HP, Jurisson M, Kallikorm R, Lember M, Lesnyak O, McCloskey E, Sanders KM, Silverman S, Solodovnikov A, Tamulaitiene M, Thomas T, Toroptsova N, Uuskula A, Tosteson ANA, Jonsson B, Kanis JA (2018) Quality of life for up to 18 months after low-energy hip, vertebral, and distal forearm fractures-results from the ICUROS. Osteoporos Int 29(3):557\u2013566","journal-title":"Osteoporos Int"},{"issue":"3","key":"5765_CR35","doi-asserted-by":"publisher","first-page":"324","DOI":"10.1016\/j.bone.2012.05.020","volume":"51","author":"L Gutierrez","year":"2012","unstructured":"Gutierrez L, Roskell N, Castellsague J, Beard S, Rycroft C, Abeysinghe S, Shannon P, Gitlin M, Robbins S (2012) Clinical burden and incremental cost of fractures in postmenopausal women in the United Kingdom. Bone 51(3):324\u2013331","journal-title":"Bone"},{"issue":"1","key":"5765_CR36","doi-asserted-by":"publisher","first-page":"99","DOI":"10.3111\/13696998.2010.547967","volume":"14","author":"L Gutierrez","year":"2011","unstructured":"Gutierrez L, Roskell N, Castellsague J, Beard S, Rycroft C, Abeysinghe S, Shannon P, Robbins S, Gitlin M (2011) Study of the incremental cost and clinical burden of hip fractures in postmenopausal women in the United Kingdom. J Med Econ 14(1):99\u2013107","journal-title":"J Med Econ"},{"issue":"11","key":"5765_CR37","doi-asserted-by":"publisher","first-page":"889","DOI":"10.1007\/s00198-003-1494-0","volume":"14","author":"JA Barrett","year":"2003","unstructured":"Barrett JA, Baron JA, Beach ML (2003) Mortality and pulmonary embolism after fracture in the elderly. Osteoporos Int 14(11):889\u2013894","journal-title":"Osteoporos Int"},{"key":"5765_CR38","unstructured":"National Institute for Health and Care Excellence (NICE) (2013), Guide to the methods of technology appraisal 2013. https:\/\/www.nice.org.uk\/process\/pmg9\/resources\/guide-to-the-methods-of-technology-appraisal-2013-pdf-2007975843781. Accessed\u00a0 24 Oct 2019"},{"key":"5765_CR39","doi-asserted-by":"publisher","first-page":"115081","DOI":"10.1016\/j.bone.2019.115081","volume":"130","author":"EL Simpson","year":"2020","unstructured":"Simpson EL, Martyn-St James M, Hamilton J, Wong R, Gittoes N, Selby P, Davis S (2020) Clinical effectiveness of denosumab, raloxifene, romosozumab, and teriparatide for the prevention of osteoporotic fragility fractures: a systematic review and network meta-analysis. Bone 130:115081","journal-title":"Bone"},{"issue":"12","key":"5765_CR40","doi-asserted-by":"publisher","first-page":"1781","DOI":"10.1007\/s00198-006-0193-z","volume":"17","author":"F Borgstrom","year":"2006","unstructured":"Borgstrom F, Jonsson B, Strom O, Kanis JA (2006) An economic evaluation of strontium ranelate in the treatment of osteoporosis in a Swedish setting: based on the results of the SOTI and TROPOS trials. Osteoporos Int 17(12):1781\u20131793","journal-title":"Osteoporos Int"},{"key":"5765_CR41","doi-asserted-by":"publisher","first-page":"394","DOI":"10.1016\/j.semarthrit.2020.02.004","volume":"50","author":"M Hiligsmann","year":"2020","unstructured":"Hiligsmann M, Williams SA, Fitzpatrick LA, Silverman SS, Weiss R, Reginster JY (2020) Cost-effectiveness of sequential treatment with abaloparatide followed by alendronate vs. alendronate monotherapy in women at increased risk of fracture: a US payer perspective. Semin Arthritis Rheum 50:394\u2013400","journal-title":"Semin Arthritis Rheum"},{"issue":"2","key":"5765_CR42","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1177\/1060028018798034","volume":"53","author":"QA Le","year":"2019","unstructured":"Le QA, Hay JW, Becker R, Wang Y (2019) Cost-effectiveness analysis of sequential treatment of abaloparatide followed by alendronate versus teriparatide followed by alendronate in postmenopausal women with osteoporosis in the United States. Ann Pharmacother 53(2):134\u2013143","journal-title":"Ann Pharmacother"},{"issue":"11","key":"5765_CR43","doi-asserted-by":"publisher","first-page":"e10233","DOI":"10.1002\/jbm4.10233","volume":"3","author":"T Mori","year":"2019","unstructured":"Mori T, Crandall CJ, Ganz DA (2019) Cost-effectiveness of sequential teriparatide\/alendronate versus alendronate-alone strategies in high-risk osteoporotic women in the US: analyzing the impact of generic\/biosimilar teriparatide. JBMR Plus 3(11):e10233","journal-title":"JBMR Plus"},{"key":"5765_CR44","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1186\/1471-2474-13-213","volume":"13","author":"DR Murphy","year":"2012","unstructured":"Murphy DR, Smolen LJ, Klein TM, Klein RW (2012) The cost effectiveness of teriparatide as a first-line treatment for glucocorticoid-induced and postmenopausal osteoporosis patients in Sweden. BMC Musculoskelet Disord 13:213","journal-title":"BMC Musculoskelet Disord"}],"container-title":["Osteoporosis International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00198-020-05765-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00198-020-05765-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00198-020-05765-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,6,10]],"date-time":"2021-06-10T18:02:59Z","timestamp":1623348179000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00198-020-05765-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1,7]]},"references-count":44,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2021,7]]}},"alternative-id":["5765"],"URL":"https:\/\/doi.org\/10.1007\/s00198-020-05765-7","relation":{},"ISSN":["0937-941X","1433-2965"],"issn-type":[{"value":"0937-941X","type":"print"},{"value":"1433-2965","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,1,7]]},"assertion":[{"value":"31 July 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 November 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 January 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"J.A.K. reports grants from Amgen, Eli Lilly and Radius Health and consulting fees from Theramex.\u00a0J.A.K. is the architect of FRAX\u00ae but has no financial interest. E.S., I.L., F.B. and O.S. are employees of Quantify Research which was contracted and paid by UCB, a pharmaceutical company marketing products for osteoporosis, to conduct the study. The authors did not receive direct payment as a result of this work outside of their normal salary payments. D.W., C.S. and M.C. are employees of UCB Pharma. B.S. is an employee of Amgen (Europe).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}}]}}